



# Interim Report

January – June 2025



LIDS<sup>TM</sup>

# LIDDS AB (publ) Interim Report January – June 2025

## April – June 2025

- Net sales amounted to 0 (0) KSEK
- The operating result for the period was -836 (-2 391) KSEK
- The net result was -733 (-2 398) KSEK corresponding to earnings per share of -0,01 (-0.02) SEK
- Cash flow from operating activities amounted to -1 594 (-2 938) KSEK
- Cash and cash equivalents amounted to 2 350 (8 009) KSEK

## January – June 2025

- Net sales amounted to 0 (0) KSEK
- The operating result for the period was -2 091 (-2 392) KSEK
- The net result was -2 044 (-2 404) KSEK corresponding to earnings per share of -0,01 (-0.02) SEK
- Cash flow from operating activities amounted to -2 333 (-3 002) KSEK

## Significant events January – June 2025

- On April 2, the board of directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202.
- Taking into account the principle of prudence, the board of directors, decided on April 10 to write down the book values of all intangible assets in LIDDS and Noviga as of 2024-12-31. This decision resulted in a deviation for the annual report compared to the published year-end report for 2024.
- Due to the reasons to believe that the company's equity was less than on-half of the registered share capital, the board of directors decided to prepare a balance sheet for liquidation purpose on April 22.
- The balance sheet for liquidation purpose prepared and reviewed by the company's auditor showed that the equity was less than half of the registered share capital and therefore the board of directors decided on April 24 to call a first control meeting.
- At the annual general meeting, at the same time first control meeting, on May 28, it was decided that the company will continue its operations and not be liquidated.

## Financial overview (the Group)

KSEK	1 April - 30 June 2025	1 April - 30 June 2024	1 January - 30 June 2025	1 January - 30 June 2024	1 January - 31 December 2024
Net sales	0	0	0	0	0
Operating result	-836	-2 391	-2 091	-2 392	-5 891
Net result	-733	-2 398	-2 044	-2 404	-5 938
Earnings per share, SEK	-0,01	-0,02	-0,01	-0,02	-0,05
Cash flow from operating activities	-1 594	-2 938	-2 333	-3 002	-5 434
Cash and cash equivalents by the end of the period	2 350	8 009	2 350	8 009	5 506

## LIDDS in Brief

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

## CEO statement

During the second quarter, the company has continued to focus on the commercialisation of the three projects Nanoimod, Nanodotax and NOV 202, as well as exploring interest in the company's listing on First North. So far, these efforts have not yet resulted in any concrete successes.

The quarter has also been characterised by extensive work on finalising the annual report, holding the annual general meeting, and managing the situation where the company's equity was found to be less than half of the share capital. Following the decision at the first control meeting to continue operations and not initiate liquidation, the company now has eight months before the question of potential liquidation needs to be reconsidered.

Mats Wiking  
CEO and CFO

## Overview of activities

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has developed a proprietary drug delivery technology for local administration of drugs, NanoZolid. Several projects in the portfolio are based on the technology. In the portfolio there is also NOV202. The NanoZolid technology improves drug efficiency by allowing a more optimal dosage locally and at the same time reducing side effects, which is of great benefit to both patients and payers. LIDDS' technology can be used across different drug classes. LIDDS offers the NanoZolid technology to partners but has also done development within the oncology area. LIDDS' leading project is Liproca Depot, which has shown good effect in Phase IIb in treating prostate cancer patients. NOV202 is a pre-clinical asset which has been developed for advanced cancer. NOV202 has shown promising synergistic anti-tumour effect together with PARP inhibitors in several tumour models. Examples of preclinical cancer models used are models for ovarian-, pancreatic- and prostate cancer. The aim has been to secure licensing deals for internally developed projects and for the technology as such.

### *NanoZolid improves efficacy and reduces side-effects*

NanoZolid addresses some of the challenges that conventional drugs face, such as systemic side effects and limited efficacy. The NanoZolid-formulated drug is delivered locally through an injection and forms a solid and safe depot that releases the active drug over a period of up to six months. The controlled release of drug compounds can be tailored to specific needs and the drugs being used. This results in a more precise treatment with fewer side effects.

### *LIDDS' portfolio is focused on oncology where the benefits of the technology are obvious*

LIDDS' own development has been focused on the oncology therapeutic area, where the benefits of the NanoZolid technology are obvious: a local and high drug dose that is administered over time with very limited side effects. The company has developed Nanodotax, a NanoZolid formulated cytotoxic drug (docetaxel), and Nanoimod, a combination therapy with checkpoint inhibitors. Both projects are in clinical phase.

### *Enables lower development costs for partners*

NanoZolid drug delivery technology offers benefits for potential partners. There is an opportunity to extend the commercial life of already existing products and to improve efficacy and reduce side-effects. A reformulation of an existing drug also means lower development costs and risks and shorter time to market.

## LIDDS oncology pipeline

### *Nanodotax*

Nanodotax is NanoZolid-formulated docetaxel which is a commonly used chemotherapeutic drug that has been approved for several oncological conditions and on the market since 1996. Nanodotax has shown to be safe and well tolerated in a Phase I study where adverse events were shown to be mild and local. Furthermore, there was an observed effect on systemic immunological biomarkers indicating that the immune system was responding positively and specifically to the drug. The project is Phase Ib ready on prostate cancer patients.

### *Nanoimod*

Nanoimod is the toll-like receptor 9 (TLR9) agonist agatolimod formulated in NanoZolid. The project is in preclinical development and has been prepared for a Phase Ib clinical study in malign melanoma in addition to treatment with Checkpoint inhibitors.

### *NOV202*

NOV202 is a small molecule developed for treatment of advanced cancer. NOV202 is in pre-clinical development and is being prepared for 28-day regulatory toxicity study and safety pharmacology study.

## Significant events during the reporting period

### *Decision to cease further development*

On April 2, the Board of Directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202. The board concluded, after extensive trials, that the company will not succeed with the investments on which the company's resources has been concentrated and therefore it will not be possible to capitalizing the company for clinical studies.

### *Decision to write-down intangible assets*

Following the board's decision on April 2, and considering the principle of prudence, the board decided on 10 April to write down the book values of intangible assets regarding development work and patents. Since the write-downs were made as of the year-end 2024/2025, this decision resulted in a deviation for the annual report compared to the earlier published year-end report 2024.

### *Decision to prepare a balance sheet for liquidation purpose*

Due to the fact that there was reason to assume that the company's equity was less than half of the registered share capital, the board decided to prepare a balance sheet for liquidation purpose on April 22.

### *Balance sheet for liquidation purposes*

The prepared balance sheet for liquidation purposes did show that company's equity was less than half of the registered share capital and therefore the board convened a first control meeting. In connection with the notice of the annual general meeting on May 28, the first control meeting for LIDDS was also called.

### *First control meeting*

At the annual general meeting, at the same time first control meeting, on May 28, it was decided, in according to the board's suggestion, that the company will continue its operations and not be liquidated.

## Financial information

### *Acquisition of Noviga Research AB*

LIDDS acquired all shares in Noviga Research AB through an issue in kind. The acquisition has been classified as a reverse takeover, which means the former owners of Noviga Research AB has the controlling influence on LIDDS. The purchase price was 10.3 MSEK, corresponding to 68,231,663 shares in LIDDS. The accounting effect is a negative goodwill. The classification also means that Noviga Research will be parent company in the group.

### *Net sales and result for the second quarter 2025*

During the second quarter of 2025, net sales amounted to 0 (0) KSEK. The operating profit for the second quarter of 2025 amounted to SEK -836 (-2,391) KSEK. In principle, all costs have decreased compared to the second quarter of 2024, but the largest decrease is due to reduced costs for personnel, consulting fees, clinical trials and production.

Depreciation and impairment of tangible and intangible assets during the second quarter of 2025 amounted to 0.0 (5,0) KSEK. Due to the board of directors' decision to write down the carrying amounts of all intangible assets as of the closing date of 2024-12-31, the second quarter is not burdened by any further depreciation or impairment.

### *The group's financial position*

The equity ratio for the Group amounted to 77 percent on June 30 2025 and equity to 2,165 KSEK.

Due to cost and personnel reductions implemented and other decisions made during 2025, the Board of Directors' assessment is that the Group's cash will be sufficient throughout 2025, provided that the company's operations continue to be conducted at the current level. Should the cost level increase during 2025, additional financing will be required earlier.

## Auxiliary information

### *LIDDS share*

LIDDS share is listed on Nasdaq First North Growth Market in Stockholm since 2014 with ticker LIDDS and ISIN code SE0001958612. Since the 18 July 2024, the trading is done through an auction five times per day. This is due to a spread in the share trading was higher than 7% during the first two quarters 2024.

Following the board's decision to cease further development of the Nanodotax, Nanoimodand NOV 202 project areas on April 2, Nasdaq announced that the share has been given observation status. The observation status was also updated on April 22 following the decision to prepare a balance sheet for liquidation purposes for the company.

The number of shares as of April 1, 2025 was 136,463,326 (136,463,326) and as of June 30, 2025 was 136,463,326 (136,463,326). The average number of shares during the second quarter of 2025 was 136,463,326 (136,463,326).

## The company's largest shareholders on 30 June 2025

Shareholders	Number of shares	Share of capital and votes (%)
Daniel Lifveredson, incl shares owned through companies	28 029 909	20,5
Ove Högberg	8 562 191	6,3
Marita Högberg	6 851 116	5,0
Stefan Rehnmark	6 632 971	4,9
Avanza Pension	6 504 004	4,8
Wikow Invest AB	6 196 517	4,5
Torbjörn Browall, incl shares owned through companies	3 600 000	2,6
Nordnet Pensionsförsäkring AB	3 464 862	2,5
Skyshire AB	3 129 017	2,3
Johan Eklund	2 826 046	2,1
Other shareholders	60 666 693	44,5
<b>Total</b>	<b>136 463 326</b>	<b>100,0</b>

*Personnel and organization*

At the end of June 2025, the number of employees was one.

*Financial calendar*

Interim Report January – September

20 November 2025

Year-end Report 2025

19 February 2026

*Transactions with related parties*

The company has not had any transactions with related parties in the second quarter 2025 other than decided fees and remuneration for the board and management and that the company rents a workplace from Excore AB at Kungssportsavenyen 22 in Gothenburg, which is also the company's address since September 2024.

*Uncertainty regarding going concern*

The combination of the board's decision to cease the development of three project areas, the write-down of all intangible assets and the preparation of a balance sheet for liquidation purposes means that there is significant uncertainty regarding the continued operation of the company's operations.

*Significant risks and uncertainties*

Apart from general uncertainties related to the sale of the assets in LIDDS AB and Noviga Research AB, there are no known tendencies, uncertainties, potential liabilities and obligations, commitments or events that can be expected to have a significant impact on the company's future prospects.

*Parent company*

The acquisition of Noviga Research AB was classified as a reverse takeover and Noviga is parent company in the group accounts. The legal parent company is still LIDDS.

*Review by auditor*

This report has not been reviewed by the company's auditor.

*Assurance by the Board of Directors*

The Board of Directors and the CEO confirm that this interim report provides a fair view of the operations, financial position and results for the parent company and the group and describes the significant risks and uncertainties that the company and the companies in the group are exposed to.

Göteborg 28 August 2025

LIDDS AB (publ) Board of Directors

Daniel Lifveredson  
Ordförande

Torbjörn Browall

Stefan Rehnmark

Lars-Inge Sjöqvist

Mats Wiking  
VD



## Group Income statement

KSEK	1 April - 30 June 2025	1 April - 30 June 2024	1 January - 30 June 2025	1 January - 30 June 2024	1 January - 31 December 2024
<b>Operating income</b>					
Net sales	0	0	0	0	0
Capitalised work on own account	0	-5	0	17	32
Other operating income	1	0	1	903	977
<b>Total</b>	<b>1</b>	<b>-5</b>	<b>1</b>	<b>920</b>	<b>1 009</b>
<b>Operating expenses</b>					
External operating expenses	-528	-1 308	-1 469	-1 523	-3 437
Personnel costs	-309	-1 047	-622	-1 159	-1 556
Depreciation and impairment of fixed assets	0	5	0	-595	-1 901
Other operating costs	0	-35	0	-35	-5
<b>Total</b>	<b>-837</b>	<b>-2 385</b>	<b>-2 092</b>	<b>-3 312</b>	<b>-6 900</b>
<b>Operating result</b>	<b>-836</b>	<b>-2 390</b>	<b>-2 091</b>	<b>-2 392</b>	<b>-5 891</b>
Financial income	21	-3	47	-3	307
Financial expenses	82	-5	0	-9	-101
<b>Total</b>	<b>103</b>	<b>-8</b>	<b>47</b>	<b>-12</b>	<b>207</b>
<b>Result after financial items</b>	<b>-733</b>	<b>-2 398</b>	<b>-2 044</b>	<b>-2 404</b>	<b>-5 684</b>
<b>Result before tax</b>	<b>-733</b>	<b>-2 398</b>	<b>-2 044</b>	<b>-2 404</b>	<b>-5 684</b>
Tax	0	0	0	0	-254
<b>Result for the period</b>	<b>-733</b>	<b>-2 398</b>	<b>-2 044</b>	<b>-2 404</b>	<b>-5 938</b>

## Group Balance sheet

KSEK	Note	30 June 2025	30 June 2024	31 December 2024
<b>ASSETS</b>				
<b>Fixed assets</b>				
Intangible assets				
Capitalized development expenditure		0	0	0
Patents		0	1 214	0
<b>Total</b>		<b>0</b>	<b>1 214</b>	<b>0</b>
Tangible assets				
Property, plant and equipment		0	14	0
<b>Total</b>		<b>0</b>	<b>14</b>	<b>0</b>
Financial assets				
Deferred tax assets		0	249	0
<b>Total</b>		<b>0</b>	<b>249</b>	<b>0</b>
<b>Total non-current assets</b>		<b>0</b>	<b>1 477</b>	<b>0</b>
<b>Current assets</b>				
<b>Current receivables</b>				
Trade receivables		0	0	0
Receivables at suppliers		0	0	0
Current tax receivables		0	475	804
Other current receivables		300	212	59
Prepaid expenses and accrued income		162	356	162
<b>Total</b>		<b>462</b>	<b>1 043</b>	<b>1 025</b>
Cash and cash equivalents		2 350	8 009	5 506
<b>Total current assets</b>		<b>2 812</b>	<b>9 052</b>	<b>6 531</b>
<b>TOTAL ASSETS</b>		<b>2 812</b>	<b>10 529</b>	<b>6 531</b>

## Group Balance sheet

KSEK	Note	30 June 2025	30 June 2024	31 December 2024
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
Share capital		7 233	7 233	7 233
Additional paid-in capital		3 504	3 629	3 629
Retained earnings (including loss for the period)		-8 571	-3 140	-6 309
<b>Total equity attributable to Parent Company shareholders</b>		<b>2 165</b>	<b>7 721</b>	<b>4 552</b>
<b>Long-term liabilities</b>				
Other liabilities		0	900	0
		0	900	0
<b>Current liabilities</b>				
Trade payables		199	684	459
Other current liabilities		195	87	664
Accrued expenses and deferred income		252	1 137	856
<b>Total</b>		<b>646</b>	<b>1 908</b>	<b>1 979</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>2 812</b>	<b>10 529</b>	<b>6 531</b>

## Consolidated statement of changes in equity

KSEK	Attributable to the Parent Company shareholders			
	Share capital	Other contributed capital	Retained earnings, incl compr income for the period	Total equity
Opening balance 1 January, 2025	7 233	3 629	-6 309	4 552
Transactions with shareholders				
Share issue	0	-125	0	-125
Reverse takeover effect	0	0	0	0
Shareholder's contribution	0	0	0	0
Result for the period	0	0	-2 262	-2 262
Total transactions with shareholders	0	-125	-2 262	-2 387
Closing balance 30 June, 2025	7 233	3 504	-8 571	2 165

## Group Cash flow statement

KSEK	1 April - 30 June 2025	1 April - 30 June 2024	1 January - 30 June 2025	1 January - 30 June 2024	1 January - 31 December 2024
<b>Operating activities</b>					
Operating profit/loss before financial items	-1 034	-2 391	-2 288	-2 392	-5 890
Interest received	22	-3	47	-3	307
Interest paid	-28	-5	-78	-9	-2
Adjustments for non-cash items					
Depreciation and impairment of intangible and tangible assets	0	0	0	-303	998
<b>Cash flow from operating activities before changes in working capital</b>	<b>-1 040</b>	<b>-2 399</b>	<b>-2 318</b>	<b>-2 706</b>	<b>-4 588</b>
<b>Cash flow from changes in working capital</b>					
Change in operating receivables	243	193	563	280	298
Change in operating liabilities	-797	-732	-577	-576	-1 145
<b>Cash flow from operating activities</b>	<b>-1 594</b>	<b>-2 938</b>	<b>-2 333</b>	<b>-3 002</b>	<b>-5 434</b>
<b>Investing activities</b>					
Acquisition of intangible assets	0	0	0	-23	-94
Acquisition of tangible assets	0	0	0	0	0
<b>Cash flow from investing activities</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>-23</b>	<b>-94</b>
<b>Financing activities</b>					
Share issue	0	0	0	0	0
Issuance costs	-125	0	-125	-280	-280
Subscription warrants	0	0	0	0	0
Net borrowings	0	0	0	0	0
Payment convertible loan	-699	0	-699	0	0
<b>Cash flow from financing activities</b>	<b>-824</b>	<b>0</b>	<b>-824</b>	<b>-280</b>	<b>-280</b>
<b>Net cash flow for the period</b>	<b>-2 418</b>	<b>-2 938</b>	<b>-3 157</b>	<b>-3 305</b>	<b>-5 809</b>
Cash and cash equivalents at the beginning of the period	4 768	10 947	5 506	191	191
Cash and cash equivalents in acquired subsidiary	0	0	0	11 124	11 124
<b>Cash and cash equivalents at the end of the period</b>	<b>2 350</b>	<b>8 009</b>	<b>2 350</b>	<b>8 009</b>	<b>5 506</b>

## Income statement Parent company

KSEK	1 April - 31 June 2025	1 April - 30 April 2024	1 January - 30 June 2025	1 January - 30 June 2024	1 January - 31 December 2025
<b>Operating income</b>					
Net sales	0	0	0	0	0
Activated work for own account	0	-3	0	30	45
Other operating income	1	0	1	0	61
<b>Total</b>	<b>1</b>	<b>-3</b>	<b>1</b>	<b>30</b>	<b>106</b>
<b>Operating expenses</b>					
External operating expenses	-670	-1 274	-1 469	-2 556	-4 309
Personnel costs	-309	-1 047	-622	-1 674	-2 070
Depreciation and impairment of fixed assets	0	-18	0	-616	-1 906
Other operating costs	0	-39	0	-35	-5
<b>Total</b>	<b>-980</b>	<b>-2 378</b>	<b>-2 092</b>	<b>-4 880</b>	<b>-8 290</b>
<b>Operating result</b>	<b>-979</b>	<b>-2 380</b>	<b>-2 091</b>	<b>-4 850</b>	<b>-8 185</b>
Impairment shares in subsidiary	-250	0	-250	0	-11 457
Financial income	21	0	47	24	334
Financial expenses	0	0	0	-3	-3
<b>Total</b>	<b>-229</b>	<b>0</b>	<b>-203</b>	<b>22</b>	<b>-11 127</b>
<b>Result after financial items</b>	<b>-1 208</b>	<b>-2 380</b>	<b>-2 294</b>	<b>-4 828</b>	<b>-19 312</b>
<b>Result before tax</b>	<b>-1 208</b>	<b>-2 380</b>	<b>-2 294</b>	<b>-4 828</b>	<b>-19 312</b>
<b>Result for the period</b>	<b>-1 208</b>	<b>-2 380</b>	<b>-2 294</b>	<b>-4 828</b>	<b>-19 312</b>

## Balance sheet parent company

KSEK	30 June 2025	30 June 2024	31 December 2024
<b>ASSETS</b>			
<b>Fixed assets</b>			
Intangible assets			
Capitalized development expenditure	0	0	0
Patents	0	1 208	0
<b>Total</b>	<b>0</b>	<b>1 208</b>	<b>0</b>
<b>Tangible assets</b>			
Property, plant and equipment	0	5	0
<b>Total</b>	<b>0</b>	<b>5</b>	<b>0</b>
<b>Financial assets</b>			
Shares in group companies	150	10 307	200
<b>Total</b>	<b>150</b>	<b>10 307</b>	<b>200</b>
<b>Total non-current assets</b>	<b>150</b>	<b>11 520</b>	<b>200</b>
<b>Current assets</b>			
<b>Current receivables</b>			
Trade receivables	0	0	0
Receivables group companies	0	293	0
Current tax receivables	51	687	690
Other current receivables	183	0	151
Prepaid expenses and accrued income	162	356	162
<b>Total</b>	<b>396</b>	<b>1 336</b>	<b>1 003</b>
Cash and cash equivalents	2 143	7 875	5 394
<b>Total current assets</b>	<b>2 539</b>	<b>9 211</b>	<b>6 396</b>
<b>TOTAL ASSETS</b>	<b>2 689</b>	<b>20 731</b>	<b>6 596</b>

## Balance sheet parent company

KSEK	30 June 2025	30 June 2024	31 December 2024
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
<b>Restricted equity</b>			
Share capital	7 233	7 233	7 233
Statutory reserve	15 223	15 223	15 222
Fund for development expenditure	0	0	0
<b>Total</b>	<b>22 456</b>	<b>22 456</b>	<b>22 456</b>
<b>Unrestricted equity</b>			
Share premium reserve	356 377	356 502	356 502
Retained earnings (including result for the period)	-376 762	-359 984	-374 467
<b>Total</b>	<b>-20 385</b>	<b>-3 482</b>	<b>-17 966</b>
<b>Total equity</b>	<b>2 071</b>	<b>18 974</b>	<b>4 490</b>
<b>Current liabilities</b>			
Trade payables	199	554	290
Liabilities group companies	0	26	1 035
Other current liabilities	195	82	23
Accrued expenses and deferred income	224	1 095	758
<b>Total</b>	<b>618</b>	<b>1 757</b>	<b>2 106</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2 689</b>	<b>20 731</b>	<b>6 596</b>



## Notes

### *Accounting principles*

From 1 January 2024 LIDDS apply K3 as accounting principle. The change from IFRS to K3 has not had any significant effects on the group's equity, reporting forms or disclosures.

### *Acquisition analysis*

In January 2024, it was announced that an agreement had been signed to acquire Noviga Research AB. The acquisition was approved at an extraordinary general meeting of LIDDS on 27 February 2024. LIDDS acquired all shares in Noviga Research AB through an issue in kind. The acquisition has been classified as a reverse acquisition, which means that the former owners of Noviga Research AB gain the controlling influence over LIDDS. For accounting purposes, Noviga Research AB is treated as the acquirer and parent company in the group following the reverse acquisition. The purchase price amounted to 10.5 MSEK, corresponding to 68,231,663 shares in LIDDS. The negative goodwill that arises as an effect of the acquisition amounts to

912 KSEK has been reported as other operating income. Because Noviga Research AB was not a parent company in the group before the acquisition of LIDDS, there are no comparison periods for the group. The group was formed on March 7, 2024, and results and cash flow are calculated in the group as of this date. Earnings per share is calculated as the group's net profit divided by the average number of shares after March 7, 136,463,326.

## For further information, please contact

Mats Wiking, CEO and CFO  
Phone: +46 (0)706 200400  
E-mail: mats.wiking@liddspharma.com

LIDDS AB (publ)  
Kungsportsavenyen 22  
411 36 GÖTEBORG

[www.liddspharma.com](http://www.liddspharma.com)

Corporate registration number: 556580–2856